(Q37162889)

18 August 2017

1 reference

title

Role of metformin for weight management in patients without type 2 diabetes (English)

1 reference

18 August 2017

0 references

0 references

1 reference

Alicia R Desilets

1

1 reference

18 August 2017

Sushmita Dhakal-Karki

series ordinal

2

1 reference

18 August 2017

Kaelen C Dunican

series ordinal

3

1 reference

18 August 2017

language of work or name

English

0 references

publication date

13 May 2008

1 reference

Annals of Pharmacotherapy

18 August 2017

1 reference

18 August 2017

42

1 reference

18 August 2017

6

1 reference

18 August 2017

817-826

1 reference

Prevalence of overweight and obesity in the United States, 1999-2004

18 August 2017

1 reference

Epidemiologic trends in overweight and obesity

21 January 2018

1 reference

Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic syndrome

21 January 2018

1 reference

Metabolic syndrome: a marker of patients at high cardiovascular risk

21 January 2018

1 reference

Treating the metabolic syndrome.

21 January 2018

1 reference

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

21 January 2018

1 reference

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

21 January 2018

1 reference

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus

21 January 2018

1 reference

Weight changes following the initiation of new anti-hyperglycaemic therapies.

21 January 2018

1 reference

Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.

21 January 2018

1 reference

Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial.

21 January 2018

1 reference

Metformin in polycystic ovary syndrome

21 January 2018

1 reference

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

21 January 2018

1 reference

Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin.

21 January 2018

1 reference

Weight-reducing Effect of Diguanides in Obese Non-diabetic Women

21 January 2018

1 reference

Comparison of fenfluramine and metformin in treatment of obesity.

21 January 2018

1 reference

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity

21 January 2018

1 reference

An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction.

21 January 2018

1 reference

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

Body size and shape changes and the risk of diabetes in the diabetes prevention program

21 January 2018

1 reference

The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.

21 January 2018

1 reference

Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity

21 January 2018

1 reference

Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease

21 January 2018

1 reference

Metabolic effects of metformin in patients with impaired glucose tolerance

21 January 2018

1 reference

Long-term (2-4 year) weight reduction with metformin plus carbohydrate-modified diet in euglycemic, hyperinsulinemic, midlife women (Syndrome W).

21 January 2018

1 reference

Impact of metformin on glucose metabolism in nondiabetic, obese African Americans: a placebo-controlled, 24-month randomized study

21 January 2018

1 reference

Effect of metformin vs. placebo treatment on serum fatty acids in non-diabetic obese insulin resistant individuals

21 January 2018

1 reference

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial

21 January 2018

1 reference

Effects of lifestyle changes and metformin on salt sensitivity and nitric oxide metabolism in obese salt-sensitive Hispanics.

21 January 2018

1 reference

Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women.

21 January 2018

1 reference

Beneficial effects of metformin in normoglycemic morbidly obese adolescents

21 January 2018

1 reference

The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes

21 January 2018

1 reference

Insulin dynamics predict body mass index and z-score response to insulin suppression or sensitization pharmacotherapy in obese children

21 January 2018

1 reference

Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents

21 January 2018

1 reference

The "obese insulin-sensitive" adolescent: importance of adiponectin and lipid partitioning

21 January 2018

1 reference

Metformin as treatment for overweight and obese adults: a systematic review

21 January 2018

1 reference

Prevalence and trends in overweight among US children and adolescents, 1999-2000

21 January 2018

1 reference

28 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1001/JAMA.288.14.1728

Identifiers

DOI

10.1345/APH.1K656

1 reference

18 August 2017

1 reference